BioNxt Solutions Inc.
BioNxt Solutions Inc.
Your view on BNXT.CN
Overview
What the company does, where it operates, and who runs it.
About BioNxt Solutions Inc.
- Industry
- Drug Manufacturers - Specialty & Generic
- Sector
- Healthcare
- CEO
- Hugh A. D. Rogers
- Headquarters
- CA
- Industry
- Drug Manufacturers - Specialty & Generic
- Sector
- Healthcare
- CEO
- Hugh A. D. Rogers
- Headquarters
- CA
BioNxt Solutions Inc. operates as a bioscience company in Germany, Switzerland, Austria, Israel, and Canada.
It develops drug delivery methods, such as transdermal patches and oral dissolvable films designed for delivery of neurological medications; and psychedelic medicine to treat mental health-related medical conditions, including depression, anxiety, addiction, and trauma-related stress disorder.
The company also develops point-of-care diagnostics comprising rapid diagnostics and biosensor screening tests for early detection and the potential for better treatment outcomes, and improved disease management; and COVID-19 PCR diagnostic kit, peri-implantitis oral biosensor, and H1N1 (swine flu) and H5N1 (avian flu) oral biosensors.
In addition, it offers analytical testing and consulting services; and engages in the pathogen and oral health diagnostic and screening test, thin film drug formulation, and psychedelic pharmaceutical production and formulation businesses.
The company was formerly known as XPhyto Therapeutics Corp. and changed its name to BioNxt Solutions Inc. in November 2022. BioNxt Solutions Inc. was incorporated in 2017 and is headquartered in Vancouver, Canada.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for BioNxt Solutions Inc., and the rating behind it. BNXT.CN last traded at C$0.63; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for BioNxt Solutions Inc.. Starting points for BioNxt Solutions Inc.: EPS -C$0.07, beta 1.18 — an Drug Manufacturers - Specialty & Generic name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for BioNxt Solutions Inc.. BioNxt Solutions Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for BioNxt Solutions Inc.. Trailing twelve-month EPS for BioNxt Solutions Inc. stands at -C$0.07. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for BioNxt Solutions Inc.. BioNxt Solutions Inc. has reported as a listed company since 2019. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
BioNxt Solutions Inc. valued side by side against its closest peers. BioNxt Solutions Inc. is measured against Drug Manufacturers - Specialty & Generic peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold BioNxt Solutions Inc., and how their positions are changing. At a C$76.7M market value, institutional positions materially move BioNxt Solutions Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by BioNxt Solutions Inc. executives and directors. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming BioNxt Solutions Inc.. BioNxt Solutions Inc. is a C$76.7M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming BioNxt Solutions Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for BioNxt Solutions Inc.. Coverage tracks BioNxt Solutions Inc. within Drug Manufacturers - Specialty & Generic (Healthcare). Press releases and market coverage, newest first.